Ornithine Aspartate

PreclinicalSmall molecule

GGeneral Hospital of Shenyang Military Region

Ornithine Aspartate is one of 45 small molecule programs targeting Encephalopathy. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EncephalopathyActive, not recruiting

EncephalopathyPreclinical

Active, not recruiting

Competition

Competitive Landscape

135 competitors in Encephalopathy

#DrugCompanyPhaseTrials

Xifaxan

SSalix

Phase 3

21 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 3

Alinia

RRomark Laboratories L.C.

Phase 3

4 4

PROCRIT

WWim Janssens

Phase 3

3 5

Cafcit

KKaken Pharmaceutical

Phase 3

1 6

Aranesp

Amgen

Phase 2

3 7

Yescarta

Gilead

Phase 2

1 8

MS Contin

Merck & Co.

Phase 2

1 9

Fludara

Sanofi

Phase 2

1 10

Fludara

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ARecruiting

Encephalopathy

NCT06483737

Clinical

Trials by Indication[1]

Encephalopathy1 trial

Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)

Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT06483737·174 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ornithine Aspartate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ornithine Aspartate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ornithine Aspartate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — General Hospital of Shenyang Military Region company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGeneral Hospital of Shenyang Military Region

Ornithine Aspartate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Encephalopathy1 trial

References

Drug Info

Quick Facts

Related News